Literature DB >> 6826719

Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit.

S G Adler, H Wang, H J Ward, A H Cohen, W A Border.   

Abstract

Intravenous cationic bovine serum albumin (BSA, pI > 9.5) induces membranous nephropathy in immunized rabbits. In this study, unimmunized rabbits received intravenous injections of cationic (n = 3) or native (n = 3) or native (n = 3) BSA, followed by ex vivo isolated left renal perfusions with sheep anti-BSA antibody. Capillary wall deposits of IgG and C3 were seen exclusively in the group receiving cationic BSA, confirming an in situ pathogenesis for cationic, BSA-induced membranous nephropathy, and demonstrating the importance of a cationic antigen for its production. We then explored whether membranous nephropathy in this model is prevented by the concomitant injection of protamine sulfate, a filterable, relatively non-immunogenic polycation. An in vitro study demonstrated that protamine sulfate incubated with glomerular basement membrane (GBM) decreased the subsequent binding of radiolabeled cationic BSA (P < 0.05). In vivo, protamine sulfate was shown to bind to anionic sites in the glomerular capillary wall after intravenous injection.Groups of rabbits received 3 wk of daily intravenous injections of cationic BSA alone (n = 15) or cationic BSA and protamine (n = 18). After 2 wk of injection of cationic BSA alone, typical membranous nephropathy developed. Granular deposits of IgG and C3 were present along the GBM associated with subepithelial dense deposits, foot process effacement, and marked albuminuria. Protamine significantly reduced or prevented the formation of deposits (P < 0.001) and in6 of 18 protamine-treated animals, existing deposits decreased or disappeared between 2 and 3 wk of injection. Albuminuria was significantly reduced in protamine-treated animals with a mean of 124+/-55 mg/24 h compared to 632+/-150 mg/24 h in the control group receiving cationic BSA alone. No significant differences between the groups were noted in serum lev9lsof IgG, C3, anti-BSA antibody, or circulating immune complex size. Studies in additional animals (n = 5) given radiolabeled cationic BSA showed that protamine did not alter the clearance of cationic BSA from serum. Control experiments showed that protamine's beneficial effects were not related to its weak anticoagulant property or toits theoretical ability to deplete tissue histamine. The administration of heparin (n = 6) or diphenhydramine (n = 6) had no effect on the development of the epimembranous lesion compared to the group receiving cationic BSA alone. In addition, homogenized whole kidney histamine content was not significantly different in the group receiving cationic BSA alone compared to the group receiving cationic BSA and protamine. This work shows that a cationic BSA-induced glomerular lesion can be produced by a renal perfusion technique involving in situ complex formation and that this process requires a cationic antigen for its development. We believe that the demonstrated beneficial effects of protamine are due to its ability to bind to glomerular anionic sites, and that this electrostatic interaction results in inhibition for the further binding of the cationic antigen, thereby limiting the severity of glomerulonephritis in this model.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6826719      PMCID: PMC436896          DOI: 10.1172/jci110793

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  The anti-heparin, anticoagulant and hypotensive properties of hexadimethrine and protamine.

Authors:  W S EGERTON; C L ROBINSON
Journal:  Lancet       Date:  1961-09-16       Impact factor: 79.321

2.  Quantitation of acute and chronic serum sickness in the rabbit.

Authors:  C B Wilson; F J Dixon
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

3.  Unilateral renal disease in the rat. I. Clinical, morphologic, and glomerular mesangial functional features of the experimental model produced by renal perfusion with aminonucleoside.

Authors:  J R Hoyer; S M Mauer; A F Michael
Journal:  J Lab Clin Med       Date:  1975-05

4.  Some hemodynamic determinants of immune complex trapping by the kidney.

Authors:  L A Hebert; C L Allhiser; S M Koethe
Journal:  Kidney Int       Date:  1978-11       Impact factor: 10.612

5.  Pathogenesis of polycation-induced alterations ("fusion") of glomerular epithelium.

Authors:  M W Seiler; H G Rennke; M A Venkatachalam; R S Cotran
Journal:  Lab Invest       Date:  1977-01       Impact factor: 5.662

Review 6.  Physiological evaluation of the isolated perfused rat kidney.

Authors:  T Maack
Journal:  Am J Physiol       Date:  1980-02

7.  Studies on the renal glomerular basement membrane. Preparation and chemical composition.

Authors:  R G Spiro
Journal:  J Biol Chem       Date:  1967-04-25       Impact factor: 5.157

8.  Passive immune complex glomerulonephritis in mice: models for various lesions found in human disease. II. Low avidity complexes and diffuse proliferative glomerulonephritis with subepithelial deposits.

Authors:  F G Germuth; E Rodriguez; C A Lorelle; E I Trump; L L Milano; O Wise
Journal:  Lab Invest       Date:  1979-10       Impact factor: 5.662

9.  The localization of circulating immune complexes in experimental serum sickness. The role of vasoactive amines and hydrodynamic forces.

Authors:  W T Kniker; C G Cochrane
Journal:  J Exp Med       Date:  1968-01-01       Impact factor: 14.307

10.  Variations in the sialic acid concentration of glomerular basement membrane preparations obtained by ultrasonic treatment.

Authors:  S C Mohos; L Skoza
Journal:  J Cell Biol       Date:  1970-05       Impact factor: 10.539

View more
  34 in total

Review 1.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

Review 2.  Pathogenesis of membranous nephropathy: recent advances and future challenges.

Authors:  Pierre Ronco; Hanna Debiec
Journal:  Nat Rev Nephrol       Date:  2012-02-28       Impact factor: 28.314

Review 3.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

Review 4.  Membranous nephropathy: the start of a paradigm shift.

Authors:  Sandra M S Herrmann; Sanjeev Sethi; Fernando C Fervenza
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-03       Impact factor: 2.894

5.  Antigenic charge as a factor in resistance to immunosuppressive therapy.

Authors:  S G Adler; H Y Wang; A H Cohen; W A Border
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

6.  The binding of immunoglobulin Fc to cationic proteins.

Authors:  S Pambakian; R N Poston
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

7.  An assessment of the influence of antigen dose in two new models of chronic serum sickness glomerulonephritis in the rat.

Authors:  P N Furness; D R Turner
Journal:  Br J Exp Pathol       Date:  1987-08

Review 8.  Mechanisms of immune deposit formation in renal glomeruli.

Authors:  M H Wener; M Mannik
Journal:  Springer Semin Immunopathol       Date:  1986

9.  Amount of antibody is critical for immune complex displacement by charge competition from both rabbit glomeruli and anionic beads.

Authors:  A S Raj; M Tuscan; B Shapiro; A Glatfelter; R Kunkel; R C Wiggins
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

10.  Antibodies to histones in systemic lupus erythematosus: prevalence, specificity, and relationship to clinical and laboratory features.

Authors:  M G Cohen; K M Pollard; J Webb
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.